Launch One Acquisition Corp. Class A Ordinary shares
LPAALaunch One Acquisition Corp. Class A Ordinary shares (LPAA) is a special purpose acquisition company (SPAC) formed to identify and acquire a target business, typically in a specified industry or sector. As a blank check company, LPAA provides public investors with the opportunity to participate in the potential growth and development of the eventual operating company through the acquisition process.
Company News
Minovia Therapeutics announced the grant of two new U.S. patents (No. 12,502,408 and No. 12,329,781) covering its proprietary Mitochondrial Augmentation Therapy (MAT) platform for treating primary mitochondrial diseases and renal diseases. The patents, with corresponding grants in Europe and Japan, strengthen the company's intellectual property p...
Minovia Therapeutics received FDA Orphan Drug Designation for MNV-201, a novel cell therapy targeting Myelodysplastic Syndrome (MDS), and announced a planned business combination with Launch One Acquisition Corp.
Minovia Therapeutics received FDA Fast Track Designation for MNV-201, its investigational compound targeting Myelodysplastic Syndrome (MDS), potentially accelerating drug development and review process.
Minovia Therapeutics, a clinical-stage biotechnology company, and Launch One Acquisition Corp., a SPAC, have announced a proposed business combination to create a Nasdaq-listed mitochondrial therapy company focused on rare diseases and longevity.
